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Multimorbidity in Antineutrophil Cytoplasmic  
Antibody–Associated Vasculitis: Results From a 
Longitudinal, Multicenter Data Linkage Study
Shifa H. Sarica,1  Peter J. Gallacher,2  Neeraj Dhaun,2  Jan Sznajd,3 John Harvie,3 John McLaren,4 
Lucy McGeoch,5 Vinod Kumar,6 Nicole Amft,7 Lars Erwig,8 Angharad Marks,9 Laura Bruno,10 York Zöllner,10 
Corri Black,1 and Neil Basu11
Objective. Antineutrophil cytoplasmic antibody–associated vasculitis (AAV) is considered a chronic, relapsing 
condition. To date, no studies have investigated multimorbidity in AAV nationally. This study was undertaken to 
characterize temporal trends in multimorbidity and report excess health care expenditures associated with 
multimorbidities in a national AAV cohort from Scotland.
Methods. Eligible patients with AAV were diagnosed between 1997 and 2017. Each patient was matched 
with up to 5 general population controls. Linked morbidity and health care expenditure data were retrieved from a 
Scottish national hospitalization repository and from published national cost data. Multimorbidity was defined as 
the development of ≥2 disorders. Prespecified morbidities, individually and together, were analyzed for risks and 
associations over time using modified Poisson regression, discrete interval analysis, and chi-square test for trend. 
The relationship between multimorbidities and health care expenditure was investigated using multivariate linear 
regression.
Results. In total, 543 patients with AAV (median age 58.7 years [range 48.9–68.0 years]; 53.6% male) and 2,672 
general population controls (median age 58.7 years [range 48.9–68.0 years]; 53.7% male) were matched and followed 
up for a median of 5.1 years. AAV patients were more likely to develop individual morbidities at all time points, but 
especially <2 years after diagnosis. The highest proportional risk observed was for osteoporosis (adjusted incidence 
rate ratio 8.0, 95% confidence interval [95% CI] 4.5–14.2). After 1 year, 23.0% of AAV patients and 9.3% of controls 
had developed multimorbidity (P < 0.0001). After 10 years, 37.0% of AAV patients and 17.3% of controls were 
reported to have multimorbidity (P < 0.0001). Multimorbidity was associated with disproportionate increases in 
health care expenditures in AAV patients. Health care expenditure was highest for AAV patients with ≥3 morbidities 
(3.89-fold increase in costs, 95% CI 2.83–5.31; P < 0.001 versus no morbidities).
Conclusion. These findings emphasize the importance of holistic care in patients with AAV, and may identify a 
potentially critical opportunity to consider early screening.
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INTRODUCTION
The antineutrophil cytoplasmic antibody (ANCA)–associated 
vasculitides (AAVs) are a set of systemic autoimmune diseases 
comprising granulomatosis with polyangiitis (GPA), microscopic 
polyangiitis (MPA), and eosinophilic granulomatosis with poly-
angiitis (EGPA) (1). With modern immunosuppressive therapy, 
these previously fatal diseases have become chronic, relapsing 
conditions in which the mean 5-year survival rate is ~70% (2).
With improved survival, AAV patients are now at an increased 
risk of multimorbidity, defined as the presence of ≥2 concurrent 
long-term disorders (3). Multimorbidity is increasingly common in the 
general population (4) and has also been described in other chronic 
inflammatory conditions, including rheumatoid arthritis (5,6). It compli-
cates chronic disease management and is associated with reduced 
functional status, decreased quality of life, and increased mortality 
(7,8). Multimorbidity also has important implications for the organi-
zation and delivery of health care, which is traditionally structured to 
optimize the management of individual diseases (9).
Previous studies have demonstrated an increased risk of several 
individual morbidities in AAV, including cardiovascular disease, dia-
betes mellitus, and venous thromboembolic disease (10–13). These 
associations are thought to be a consequence of chronic inflamma-
tion or the increasingly potent and toxic medications used to treat 
AAV (14). However, to our knowledge, no studies have yet investi-
gated the frequency or burden of multimorbidity in AAV patients. In 
this Scottish national, multicenter data linkage study, we compare 
temporal trends in the incidence of a wide range of individual mor-
bidities and multimorbidity between AAV patients and matched 
general population controls, and report the cost of excess resource 
consumption attributable to multimorbidity in AAV patients.
PATIENTS AND METHODS
Ethical considerations. This study was conducted 
in compliance with the Declaration of Helsinki. Approval was 
received from the Scotland Research Ethics Committee A (ref-
erence no. 15-SS-0152). Individual patient consent was not 
required as the research was approved by the Public Bene-
fit and Privacy Panel for Health and Social Care, which over-
sees studies accessing anonymized health care data held by 
the NHS Scotland. Information governance, confidentiality, 
and data protection were undertaken according to the Data 
Protection Act of 1998. All study data were analyzed and held 
within a unique, secure national safe-haven environment (15) 
administered by the Electronic Data and Innovation Service, 
NHS Scotland.
Study design and data linkage. We performed a retro-
spective, matched-cohort, population-based data linkage study 
using routine health care data from multiple national registries 
in Scotland (see the flow diagram in Supplementary Figure 1, 
available on the Arthritis & Rheumatology website at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41557/ abstract). Record  linkage 
was conducted by investigators at NHS Scotland, using a 
robust methodology that has previously been shown to produce 
highly accurate and complete data (16,17).
Study population. AAV patients were identified by clini-
cians using the European Medicines Agency criteria (18) in 7 sec-
ondary and tertiary care hospitals across Scotland. Patients were 
eligible for inclusion if they were diagnosed as having AAV after 
January 1, 1995 and were age ≥16 years at the time of data link-
age. The date of AAV diagnosis was assigned as the index date. 
Each patient was matched with at least 1, but up to 5, general 
population controls based on age (±2 years), sex, and postal code 
of residence. General population controls were assigned the same 
index date as their matched AAV patient.
Study follow-up. Patients were followed up from the index 
date until their date of death or February 28, 2017, whichever 
came first. Information regarding cause of death was obtained via 
data linkage from the National Records of Scotland death registry, 
which records all deaths in Scotland (19).
Definition and identification of individual morbidi-
ties and multimorbidity. Morbidities were defined as clinically 
distinct diseases co-occurring with AAV, but which were not a 
direct complication of AAV itself (e.g., chronic kidney disease, neu-
ropathy, arthritis, and sino-nasal disease). Our analysis focused a 
priori on a set of 12 individual morbidities of public health concern 
in elderly populations (as shown in Supplementary Figure 1 [http://
onlin elibr ary.wiley.com/doi/10.1002/art.41557/ abstract]), which 
were identified following discussions between senior coauthors 
and an extensive review of the relevant literature describing mul-
timorbidity in AAV (20,21). The majority of these morbidities have 
previously been shown to be identifiable from administrative data 
sets with moderate-to-high validity (21). Multimorbidity was defined 
as the presence of ≥2 disorders and was determined by summing 
each patient’s individual morbidities at specific time points (years 
1, 2, 5, and 10). Information regarding each patient’s morbidities 
was obtained via data linkage with a Scottish national, population- 
based hospitalization repository. This registry holds information on 
the discharge codes of all hospitalizations in Scotland since the 
1980s and details up to 6 diagnoses per admission (22). The first 
diagnosis corresponds to the primary reason for hospitalization, 
while the remaining diagnoses capture information regarding the 
patient’s morbidities. All diagnostic codes recorded for each hos-
pitalization were included in this analysis.
Morbidities were identified using previously validated Inter-
national Classification of Diseases, Ninth Revision (ICD-9) codes 
(ICD-9 pre-1996; ICD-10 post-1996) (as listed in Supplemen-
tary Table 1, available on the Arthritis & Rheumatology website 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41557/ abstract) 
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(21,23,24). The first date that a relevant diagnostic code appeared 
in a patient’s record was assigned as the incident date for that 
specific morbidity. Individual morbidities identified during the 5 
years prior to the patient’s enrollment in the study (i.e., prior to the 
index date) were classified as preexisting morbidities and were 
thus excluded from the analysis. This duration of “look-back” 
period has previously been shown to allow incident morbidities 
to be distinguished from prevalent morbidities with accuracy and 
reliability (25).
Determination of health care expenditure. Count 
data regarding the number of outpatient encounters, number 
of inpatient hospitalizations, and overall length of inpatient stay 
(on both general medical wards and intensive care units) were 
obtained via data linkage with the Scottish outpatients and hos-
pitalizations registries for each study year (see Supplementary 
Figure 1 [http://onlin elibr ary.wiley.com/doi/10.1002/art.41557/ 
abstract]). The NHS Scottish Health Service Costs Book was used 
to obtain annual tariffs for resource consumption (26). Tariffs were 
inflated to 2016 values using the Hospital and Community Health 
Service Index. Inaccessible data regarding tariffs from pre-2002 
were estimated using the 2002 tariff as the reference for deflation.
Statistical analysis. Baseline characteristics of the AAV 
patients and matched general population controls were summa-
rized. Incident morbidities were summed for each participant and 
used to derive an ordinal variable representing patients with 0, 1, 
2, or ≥3 morbidities. Differences in the proportions of AAV patients 
and general population controls in each of these categories were 
compared using a chi-square test for trend.
The overall risk of individual morbidities in AAV patients 
and matched controls was compared using modified Poisson 
regression models, adjusted for age, sex, and local health board 
(27,28). Discrete-time analysis was conducted with follow-up at 1, 
2, 5, and 10 years using Lexis expansions (29). These time points 
were selected a priori based on current treatment guidelines on the 
duration of induction and remission therapy in AAV (30), in order to 
provide sufficient granularity to observe potential temporal changes 
in the occurrence of morbidities. The incidence rates for individ-
ual morbidities at each interval were calculated by dividing the 
number of morbidities observed in each interval by person-years 
of follow-up included in each interval. Data are expressed as the 
adjusted incidence rate ratio (IRR) with 95% confidence interval 
(95% CI), computed using the Poisson assumption (31).
A multivariate linear regression model, adjusted for age, 
sex, and socioeconomic deprivation status (for further clarifi-
cation, see Supplementary Methods, available on the Arthri-
tis & Rheumatology website at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41557/ abstract), was created to determine 
the relationship between number of individual morbidities and 
health care expenditure. As the residuals were not normally 
distributed, the continuous dependent variable “health care 
expenditure” was log-transformed using the natural logarithm. 
Homoscedasticity was evaluated using the Breusch-Pagan 
test. All analyses were performed in Stata (version 14) (32) and 
R (version 3.6.1) (33).
RESULTS
Patient characteristics. In total, 543 patients with AAV 
(median age at index date 58.7 years [range 48.9–68.0 years]; 
53.6% male) were matched with 2,672 general population con-
trols (median age at index date 58.7 years [range 48.9–68.0 
years]; 53.7% male) and followed up for a median of 5.1 years 
(range 2.5–9.4 years) (Table 1). Of the patients with AAV, 316 
(58.2%) had GPA, 157 (28.9%) had MPA, and 68 (12.5%) had 
EGPA. ANCAs with the proteinase 3 specificity were present in 
52.7% of patients (286 of 543) and ANCAs with the myeloperoxi-
dase specificity were present in 34.6% of patients (188 of 543). A 
total of 12.0% of patients with AAV (65 of 543) were classified as 
ANCA negative.
Risk of developing individual morbidities in AAV. 
The risk of developing most individual morbidities was higher 
in AAV patients than in general population controls (Figure 1). 
The morbidity most frequently observed in AAV patients during 
study follow-up was hypertension (19.7% of AAV patients [92 of 
466] versus 9.4% of general population controls [234 of 2,482]; 
P < 0.0001) (Table 2). However, the highest proportional risk differ-
ence between AAV patients and general population controls was 
observed for osteoporosis (adjusted IRR 8.0, 95% CI 4.5–14.2) 
(Figure 1).






No. of participants 543 2,672
Male sex, no. (%) 291 (53.6) 1,434 (53.7)
Age at index, median 
(IQR) years
58.7 (48.9–68.0) 58.7 (48.9–68.0)
Follow-up, median 
(IQR) years
5.1 (2.5–9.4) 5.2 (2.5–9.5)










ANCA negative 65 (12.0)
Missing 4 (0.7)
* AAV = antineutrophil cytoplasmic antibody (ANCA)–associated 
vasculitis; GPA = granulomatosis with polyangiitis; MPA = microscopic 
polyangiitis; EGPA = eosinophilic granulomatosis with polyangiitis; 
PR3 = proteinase 3; MPO = myeloperoxidase; NA = not applicable. 
SARICA ET AL 4       |
A sensitivity analysis exploring the proportional risk of hos-
pital admissions due to hip fractures was performed to validate 
this finding. The risk of hip fractures in AAV patients was found 
to be twice that in general population controls (adjusted IRR 2.0, 
95% CI 1.1–3.7).
To explore the influence of surveillance bias, a further 
sensitivity analysis was performed to evaluate the propor-
tional risk of hypothyroidism and stroke in only those patients 
and controls with a record of at least 1 hospitalization during 
study follow-up (see Supplementary Results, available on the 
Arthritis & Rheumatology website at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41557/ abstract).
Temporal trends in individual morbidities and mul-
timorbidity in AAV. Figure 2 illustrates trends in the incidence of 
individual morbidities over time following the diagnosis of AAV. In 
general, the highest incidence for most morbidities was observed 
during the first 2 years of follow-up. This was especially marked 
for hypertension and hypothyroidism. However, a further increase 
in the incidence of several morbidities, including cardiovascular 
disease, diabetes mellitus, and chronic pulmonary disease, was 
also noted at 5–10 years after AAV diagnosis.
The proportion of study participants developing at least 1 
incident morbidity increased over time in both AAV patients and 
general population controls (Figure 3). However, at every time 
point, AAV patients developed a significantly higher number of 
individual morbidities compared to general population controls 
(P < 0.0001 for all time points) (Figure 3).
Multimorbidity (defined as the presence of ≥2 disorders) 
was also more common in AAV patients than in general pop-
ulation controls at all time points. For example, after 1 year of 
follow-up, 23.0% of AAV patients (125 of 543) could be con-
sidered to have developed multimorbidity versus 9.3% of gen-
eral population controls (248 of 2,672) (P < 0.0001). Ten years 
after diagnosis, a further 37.0% of AAV patients (101 of 273) 
had developed multimorbidity, compared with 17.3% of general 
population controls (235 of 1,362) (P < 0.0001).
Health care expenditure attributable to multi-
morbidity in AAV patients. Figure 4 illustrates the rela-
tionship between the number of individual incident morbidities 
and the total cost (in British pound sterling) of excess resource 
Figure 1. Comparison of the incidence of individual morbidities between patients with antineutrophil cytoplasmic antibody–associated 
vasculitis (AAV) and general population controls. Results are incidence rate ratios with 95% confidence intervals (95% CIs), adjusted for age, 
sex, and local health board. The rate of incident morbidity in the general population controls was set as the referent.
Table 2. Comparison of incident morbidities between AAV patients 








49 (9.6) 119 (5.0) <0.0001
Cardiovascular 
disease
61 (12.6) 236 (9.5) 0.042
Chronic pulmonary 
disease
46 (9.7) 120 (4.7) <0.0001
Depression <5 (<0.9) 21 (0.8) 0.749
Diabetes mellitus 37 (7.2) 94 (3.6) <0.0001
Dementia 6 (1.1) 32 (1.2) 0.846
Hypertension 92 (19.7) 234 (9.4) <0.0001
Hypothyroidism 21 (4.0) 34 (1.3) <0.0001
Osteoporosis 29 (5.4) 22 (0.8) <0.0001




31 (5.8) 30 (1.1) <0.0001
Valvular disease 46 (8.7) 80 (3.0) <0.0001
* Values are the number (%) of subjects. AAV = antineutrophil 
cytoplasmic antibody–associated vasculitis. 
† A full list of conditions encompassed by this term is provided in the 
Supplementary materials. 
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consumption due to outpatient encounters and inpatient hos-
pitalizations (on both general medical wards and intensive care 
units) in 502 AAV patients during study follow-up. Multivariate lin-
ear regression modeling confirmed that the development of mul-
timorbidity was associated with a proportionally higher cost of 
excess resource consumption in AAV patients (results shown in 
Supplementary Table 2, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41557/ 
abstract). Compared to the development of no morbidities during 
study follow-up, the development of 2 morbidities was associ-
ated with a 2.78-fold increase (95% CI 2.09–3.71) (P < 0.0001) 
in health care expenditure in AAV patients, while the develop-
ment of ≥3 morbidities was associated with a 3.89-fold increase 
(95% CI 2.83–5.31; P < 0.001) in health care expenditure in AAV 
patients. The increases in total health care expenditure observed 
with the development of multimorbidity were predominantly 
related to increases in inpatient, rather than outpatient, health 
care expenditure (see Supplementary Results and Supplemen-
tary Tables 3 and 4, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41557/ 
abstract).
DISCUSSION
This is the first study to describe longitudinal trends in the 
incidence of multimorbidity and report the health care expendi-
ture attributable to multimorbidity in a large national cohort of 
AAV patients from Scotland. We report a number of important 
observations.
First, AAV patients are at a significant risk of developing 
 individual morbidities throughout their disease course, but espe-
cially in the first 2 years following diagnosis. Second, multimorbid-
ity (the presence of ≥2 disorders) is common in AAV patients and 
significantly increases in frequency over time. Indeed, it affected 
almost one-quarter of the AAV patients in their first year after diag-
nosis, and affected more than one-third of patients by year 10 
of follow-up. Third, multimorbidity is associated with an ~3-fold 
increase in excess health care expenditure in AAV patients.
Figure 2. Temporal trends in the incidence of individual morbidities in patients with antineutrophil cytoplasmic antibody–associated vasculitis 
(AAV) and general population controls. Scale of the y-axis is different for hypertension. Numbers of subjects at each time point are shown below 
the graphs.
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Uniquely, our study demonstrates that AAV patients are at an 
increased risk of developing multimorbidity compared to  general 
population controls. While the impact of multimorbidity has not 
been studied previously in AAV, we also found that multimor-
bidity is associated with a disproportionate increase in the cost 
of overall excess resource consumption. In comparison to AAV 
patients with no morbidities, the development of multimorbidity in 
AAV patients is associated with a 2–4-fold increase in total health 
care expenditure, but a 3–5-fold increase in inpatient health care 
expenditure. Relevant studies in other chronic disease popula-
tions, for example in patients with cardiovascular disease (34) or 
chronic kidney disease (35), have also demonstrated that multi-
morbidity is becoming the rule rather than the exception (9,36). 
The implications of this are significant, given the striking associ-
ation of multimorbidity with polypharmacy, greater resource con-
sumption, reduced quality of life, and poorer outcomes (7–9,37).
Our findings are also consistent with previous assessments 
of individual morbidities in AAV. In relation to the risk of cardio-
vascular disease, we demonstrate an increased risk in both early 
and late stages of AAV (10,11,38). Uniquely, our study extends 
these findings to other cardiovascular disorders, including valvu-
lar disease and arrhythmias, both of which demonstrate a similar 
bimodal risk pattern over time. Although primary cardiovascular 
disease is relatively uncommon in AAV, the observed risk may 
be due to a combination of chronic inflammation and glucocor-
ticoid toxicity (39,40). It is possible that these findings are partly 
explained by surveillance bias. For example, valvular heart dis-
ease may have been diagnosed during routine echocardiography, 
an investigation that AAV patients are more likely to undergo than 
general population controls.
As general population controls were not selected from the 
time point of a new diagnosis, the increased risk observed for 
several morbidities early in the AAV disease course may also be 
explained by surveillance bias, due to the additional investigations 
performed in AAV patients following their index diagnosis. For 
example, AAV patients are commonly tested for hypothyroidism 
as part of their diagnostic evaluation. Nevertheless, an increased 
risk of hypothyroidism has previously been demonstrated in AAV 
patients prior to diagnosis, which aligns with accumulating evi-
dence supporting shared mechanisms across the autoimmune 
disease spectrum (41). Similarly, the increased risk of osteo-
porosis in AAV patients observed in the present study may be 
related to current guideline recommendations for dual energy 
x-ray absorptiometry scans when patients commence treatment 
with glucocorticoids (30). Hip fractures are a reliable surrogate end 
point unlikely to be affected by surveillance bias and, as a result, 
we performed a sensitivity analysis to evaluate the risk of hip frac-
tures during follow-up. Interestingly, we observed that the risk of 
hip fractures in AAV patients was twice that of general popula-
tion controls—verifying our finding that osteoporosis risk is indeed 
increased in AAV patients.
Our findings have important implications for clinical prac-
tice. Specifically, the results of our temporal analysis highlight the 
importance of early screening for many common conditions in 
AAV patients, while also highlighting the significance of late- onset 
cardiovascular disease and diabetes mellitus. Our observation 
that peptic ulcer disease is no more likely in AAV patients than in 
general population controls, despite the frequent administration 
of high-dose glucocorticoids to patients with AAV, also appears 
to reflect the relative success of prophylactic therapies aimed at 
Figure 3. Prevalence of morbidities at baseline and cumulative incidence of morbidities and multimorbidity at 1, 2, 5, and 10 years in patients 
with antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and general population controls. P < 0.0001 by chi-square test for trend 
for all time points. Numbers of subjects at risk at each time point are shown below the graph.
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suppressing gastric acid secretion. Therefore, our data encourage 
similar preventative strategies for other morbidities.
Further research is required to understand what exact mecha-
nisms underlie the increased risk of multimorbidity observed in AAV 
patients in the present study. Given the relationship between mul-
timorbidity and adverse pharmacologic effects, such work could 
ultimately incentivize a shift toward a reduction in the use of phar-
macologic therapies associated with numerous adverse effects, 
such as glucocorticoids. Indeed, with the transformation of AAV 
into a chronic disease, it is timely to prioritize a more holistic 
approach toward the management of AAV. This is analogous to 
the concept of “cancer survivorship,” which has been established 
in oncology in response to improvements in cancer-related mor-
tality. The overarching aim of cancer survivorship is to address the 
physical, psychological, and social health  burden that arises as a 
consequence of cancer patients living longer (42). Clinicians must 
therefore consider how best to organize and deliver health care 
to AAV patients, in order to fully address both their multimorbid-
ity and their primary disease. Greater collaboration with primary 
care providers is likely be critical to the potential success of any 
such move toward a more holistic approach to patient care in AAV.
Our study has several important strengths. Utilizing one of 
the largest cohorts of AAV patients, we adopted a comprehensive 
approach for improving our understanding of the burden associ-
ated with multimorbidity in AAV patients. Indeed, our method for 
identifying AAV patients suitable for inclusion in our cohort was 
also robust. In addition, we assessed prevalent morbidity burden 
using a validated length of “look-back” period (25) and previously 
verified ICD9/ICD-10 discharge coding (21,23,24), which has a 
reported accuracy of ~96% for common diagnoses recorded in 
the SMR01 data set (43).
However, a number of limitations must be considered. First, 
our study identified morbidities from secondary care records, 
which mostly capture major disorders. Despite including all 
available diagnostic codes, relatively minor disorders may have 
been overlooked by secondary care coders, and therefore our 
incidence estimates are likely to be conservative. However, this 
will have affected AAV patients and general population controls 
equally.
Second, given the higher hospitalization rate observed 
among AAV patients (98% versus 79% of general population con-
trols), the IRRs for conditions managed in primary care are likely 
to be overestimates. To address this limitation, we performed a 
sensitivity analysis including only those patients and controls with 
a hospitalization record, and found that the degree of overestima-
tion was small for hypothyroidism, stroke, and myocardial infarc-
tion (see Supplementary Results [http://onlin elibr ary.wiley.com/
doi/10.1002/art.41557/ abstract]).
Third, patients not hospitalized in the 5 years prior to their 
index date were classified as having no preexisting morbidities. 
It is therefore difficult to be certain exactly when these patients 
developed “incident” morbidities. To limit the impact of this, we 
utilized a validated, fixed 5-year look-back period (25) to stan-
dardize the identification of baseline morbidities across all patients.
Fourth, study follow-up was limited to a median period of 5 
years, which may partly explain why we failed to demonstrate an 
increased risk of depression or dementia in AAV patients. Although 
sufficient for identifying relatively acute-onset conditions, longer 
follow-up is required to reliably establish the occurrence of more 
gradual-onset disorders, such as depression and dementia.
Fifth, despite being one of the largest studies of its kind, we 
were unable to undertake stratified analysis by AAV type, due to a 
lack of statistical power.
In conclusion, this novel study is the most comprehensive 
and detailed analysis of multimorbidity in AAV patients to date. 
AAV patients are at a high risk of developing individual morbidi-
ties, especially early in their disease course. Multimorbidity is also 
common in AAV patients and is associated with disproportion-
ate increases in health care expenditure. Our findings emphasize 
the importance of holistic care in AAV patients and the need to 
 consider early screening for other conditions.
Figure 4. Alluvial plot illustrating the relationship between number 
of incident morbidities and total excess health care expenditure 
during the study follow-up in patients with antineutrophil cytoplasmic 
antibody–associated vasculitis (n = 502).
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